NCT00416273 - A Study of Bortezomib as Consolidation Therapy in Patients With Multiple Myeloma | Biotech Hunter

Enrollment

217

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2013

Conditions

Multiple Myeloma

Interventions

DRUG

Bortezomib

Bortezomib will be administered as 1.6 mg/m2 per body surface area on the days 1, 8, 15, 22 for the duration of 4 therapy cycles.

DRUG

No intervention

Participants in the observation group will be observed and will not receive any consolidation therapy.

Trial Locations (38)

Unknown

Augsburg

Bamberg

Berg

Berlin

Bremen

Cologne

Dresden

Duisburg

Erlangen

Eschweiler

Frankfurt am Main

Freiburg im Breisgau

Goch

Göttingen

Greifswald

Halle

Hamburg

Hamm

Hanover

Homburg

Jena

Karlsruhe

Kempten

Kiel

Magdeburg

Mainz

Mutlangen

München

Münster

Nuremberg

Oldenburg

Regensburg

Rostock

Stuttgart

Ulm

Villingen-Schwenningen

Wiesbaden

Würzburg

All Listed Sponsors

lead

Janssen-Cilag G.m.b.H

INDUSTRY